Advertisement







Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2001; 37:863-870
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Higashi, Y.
Right arrow Articles by Oshima, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higashi, Y.
Right arrow Articles by Oshima, T.

CLINICAL STUDY: HYPERTENSION

Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function

Yukihito Higashi, MD, PhD*, Shota Sasaki, MD*, Keigo Nakagawa, MD*, Hideo Matsuura, MD, PhD*, Goro Kajiyama, MD, PhD* and Tetsuya Oshima, PhD{dagger}

* First Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
{dagger} Department of Clinical Laboratory Medicine, Hiroshima University School of Medicine, Hiroshima, Japan

Manuscript received June 7, 2000; revised manuscript received September 22, 2000, accepted November 3, 2000.

Reprint requests and correspondence: Dr. Yukihito Higashi, Hiroshima University School of Medicine, First Department of Internal Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
yhigashi{at}mcai.med.hiroshima-u.ac.jp

OBJECTIVES

The purpose of this study was to evaluate the effects of the angiotensin-converting enzyme (ACE) inhibitor imidapril and the calcium antagonist amlodipine on endothelial function before and after 2, 4, 8, 12, 24 and 48 weeks of treatment.

BACKGROUND

There are limited data on whether and how long endothelial function is improved after initiation of ACE inhibitor treatment and how the grade of endothelial function further progresses after improvement of endothelial dysfunction in patients with essential hypertension.

METHODS

The forearm blood flow (FBF) was measured in 25 patients with essential hypertension and in 25 normotensive subjects by using strain-gauge plethysmography during reactive hyperemia (RH) (280 mm Hg for 5 min) and after sublingual administration of nitroglycerin (NTG, 0.3 mg).

RESULTS

The FBF of patients with essential hypertension during RH was significantly less than that of normotensive subjects. The increase in FBF after sublingual NTG was similar in both groups. Both imidapril (n = 13) and amlodipine (n = 12) significantly reduced systolic blood pressure and diastolic after eight weeks of treatment from the pretreatment values. Forearm vascular resistance was significantly decreased after two weeks of treatment. Imidapril significantly augmented RH after 12 weeks of treatment from the pretreatment values (31.6 ± 5.7 to 38.2 ± 6.0 ml/min per 100 ml tissue, p < 0.05), whereas amlodipine did not alter RH for each treatment period. The ability of imidapril to improve RH was maintained throughout the 48-week treatment period. There was no significant difference in RH at 12, 24 and 48 weeks. The increase in FBF after sublingual administration of NTG was similar in all treatment periods for the two groups. The infusion of NG-monomethyl-L-arginine, a nitric oxide (NO) synthase inhibitor, abolished the enhancement of RH in hypertensive patients treated with imidapril.

CONCLUSIONS

These findings suggest that the ACE inhibitor imidapril augments RH after 12 weeks of treatment in patients with essential hypertension and that this ACE inhibitor-induced augmentation of RH may be due to an increase in NO.

Abbreviations and Acronyms
  ACE = angiotensin-converting enzyme
  BP = blood pressure
  EDHF = endothelium-dependent hyperpolarizing factor
  FBF = forearm blood flow
  FVR = forearm vascular resistance
  L-NMMA = NG-monomethyl-L-arginine
  NO = nitric oxide
  NTG = nitroglycerin
  RH = reactive hyperemia




This article has been cited by other articles:


Home page
J. Am. Coll. Nutr.Home page
D. Tousoulis, C. Antoniades, K. Marinou, C. Vasiliadou, G. Bouras, E. Stefanadi, G. Latsios, G. Siasos, K. Toutouzas, and C. Stefanadis
Methionine-Loading Rapidly Impairs Endothelial Function, by Mechanisms Independent of Endothelin-1: Evidence for an Association of Fasting Total Homocysteine with Plasma Endothelin-1 Levels
J. Am. Coll. Nutr., June 1, 2008; 27(3): 379 - 386.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
N. Toda, K. Ayajiki, and T. Okamura
Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation
Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
C. Antoniades, D. Tousoulis, K. Marinou, C. Vasiliadou, C. Tentolouris, G. Bouras, C. Pitsavos, and C. Stefanadis
Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines.
Am. J. Clinical Nutrition, October 1, 2006; 84(4): 781 - 788.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
D. Tousoulis, C. Antoniades, C. Vassiliadou, M. Toutouza, C. Pitsavos, C. Tentolouris, A. Trikas, and C. Stefanadis
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure
Eur J Heart Fail, December 1, 2005; 7(7): 1126 - 1132.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. Maas
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)
Vascular Medicine, July 1, 2005; 10(1_suppl): S49 - S57.
[Abstract] [PDF]


Home page
Vasc MedHome page
R. Maas
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA)
Vascular Medicine, May 1, 2005; 10(2_suppl): S49 - S57.
[Abstract] [PDF]


Home page
HeartHome page
D Tousoulis, C Antoniades, and C Stefanadis
Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques
Heart, April 1, 2005; 91(4): 553 - 558.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. J. Oliver and D. J. Webb
Noninvasive Assessment of Arterial Stiffness and Risk of Atherosclerotic Events
Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 554 - 566.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Sanada, Y. Higashi, K. Nakagawa, M. Tsuda, I. Kodama, M. Kimura, K. Chayama, and K. Ohama
A Comparison of Low-Dose and Standard-Dose Oral Estrogen on Forearm Endothelial Function in Early Postmenopausal Women
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1303 - 1309.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Wassmann, S. Hilgers, U. Laufs, M. Bohm, and G. Nickenig
Angiotensin II Type 1 Receptor Antagonism Improves Hypercholesterolemia-Associated Endothelial Dysfunction
Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1208 - 1212.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
Y. Higashi, S. Sasaki, K. Nakagawa, H. Matsuura, T. Oshima, and K. Chayama
Endothelial Function and Oxidative Stress in Renovascular Hypertension
N. Engl. J. Med., June 20, 2002; 346(25): 1954 - 1962.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement